Episode 2 - The future is now-combination therapies in DLBCL

Episode 4 - Guiding principles when sequencing treatments in DLBCL

Gain practical insights into treatment sequencing in the evolving DLBCL landscape. In this episode, Dr. Marin Xavier shares her approach to navigating novel therapies—such as antibody drug conjugates (ADCs) and bispecifics—with a focus on patients who may not be ready for CAR T-cell therapy. Learn how she makes real-world decisions in a complex and rapidly changing field. Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood Guest: Dr. Marin Xavier, Hematologist and Oncologist, Scripps Health, San Diego

Episode 3 - Managing novel DLBCL therapies in the community - what good looks like

Integrating novel therapies like bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) into community oncology practices can be a complex process. On this episode of Bridges, Dr. Lunning and Dr. Graff speak with Dr. Iqra Choudary about how she integrated BsAbs and ADCs into her practice with a proactive multidisciplinary team, strong safety protocols, comprehensive staff training, and strategic hospital partnerships.   Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood Guest: Dr. Iqra Choudary, board certified in Internal Medicine, Hematology-Oncology Associates of Central New York

Episode 2 - The future is now-combination therapies in DLBCL

Interested in novel combination therapies for patients with diffuse large B-cell lymphoma (DLBCL)? Dr. Marie Hu joins the podcast to share her perspectives on emerging treatments and the impact of stronger academic-community collaborations on patient care for relapsed and refractory patients with DLBCL. Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood Guest: Dr. Marie Hu, Assistant Professor of Medicine, University of Minnesota

Episode 1 - Evolution of Antibody Drug Conjugates

Join us for a high-level look at antibody drug conjugates (ADCs) in lymphoma treatment. Dr. Weiyun Ai provides a detailed overview of ADCs—a pioneering method that can change how lymphoma is treated. Learn how they target cancer, overcome obstacles, and pave the way for developing new combination therapies. Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood Guest: Dr. Weiyun Ai, Professor of Medicine, University of California, San Francisco